Oncology Small Molecule Drugs Market Forecast, Trend Analysis & Competition Tracking: Global Market Insights 2019 to 2029

  • Published : Jun-2019
  • Tables : 53
  • Figures : 215
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT3747MR
  • Format : ppt

Oncology Small Molecule Drugs Market in Numbers 

  • Global sales of oncology small molecule drugs were valued at ~US$ 63 Bn in 2018, in line with the widespread prevalence of cancer and subsequent need for oral, easily absorbable, and effective medicines.
  • The market for oncology small molecule drugs is envisaged to register ~6% CAGR through 2029, primarily driven by rapid technological advancement in healthcare sector that continues to pave way for new and improved product development.
  • North America, spearheaded by the U.S., is anticipated to remain the leading as well as high growth market for oncology small molecule drugs during the foreseeable period. With high treatment seeking rate and favorable reimbursement scenarios for cancer treatment, the US is estimated to witness revenues worth ~US$ 30 Bn in 2019.
  • Addition of new products to portfolios through partnerships, and increasing the number of molecules in early phase of drug development will remain among the key trends shaping the competition landscape of oncology small molecule drugs market. 
oncology small molecule drugs market snapshot

Competition Landscape 

According to the Fact.MR study, the oncology small molecule drugs market will continue to remain consolidated with top five players, including Novartis Ag, Astrazeneca, Genentech, Pfizer, and Abbvie, accounting for ~47% market value share.  These players are emphasizing strong regional presence, robust R&D, new launches, and diverse offerings to stay ahead of the competition in oncology small molecule drugs market, which compels companies to enter strategic collaborations with recognized biopharma companies. For instance, recently in June 2019, Pfizer announced the decision to buy the oncology specialist Array BioPharma, marking an important acquisition beefing up the former’s oncology offerings with two marketed drugs - BRAF inhibitor Braftovi, and MEK inhibitor Mektovi. These two drugs have been approved as a part of the combination treatment for melanoma, and have delivered proven positive results in case of colon cancer. 

Mid-level players, such as Roche, Bayer, Genzyme Corporation (Sanofi), and Eli Lilly and Company, are focusing on penetration into developing economies, looking at their market attractiveness. Development of novel treatment options to appeal a wider patient pool will be a priority strategy adopted by prominent players in this category. The market entrants, on the other hand, are likely to remain focused on expansion of the manufacturing capacities to better their foothold in local and regional markets. Amid the growing competition in the oncology small molecule drugs market, partakers are vying to squeeze profit margins by developing low-cost variants, with an objective to firm up in developing regions.    

oncology small molecule drugs market competition analysis

For more valuable insights into the oncology small molecule drugs market, request for the report sample 

Key Factors Shaping Growth of the Oncology Small Molecule Drugs Market 

  • High prevalence of cancer, coupled with the notable preference for more effective drugs that can easily enter and get absorbed in the cells is primarily boosting sales of oncology small molecule drugs.
  • Increasing awareness about the availability of novel and easily absorbable drugs for cancer treatment is providing an impetus to oncology small molecule drugs sales.
  • Modulating the immune system via a small-molecule approach offers several unique benefits that are complementary to, and potentially synergistic with, biologic modalities. An increasing number of biopharma companies are thus utilizing ‘selective targeting small molecules’ that accurately exploit the vulnerabilities in cancer cells. Such a pragmatic approach towards cancer is likely to create a plethora of opportunities in terms of new product developments in the oncology small molecule drugs market.
  • While small molecules account for ~70% of the newly developed molecular entities (NME), as approved by the FDA in 2018, it is highly likely that industry giants will refocus their oncology drug development strategies around the use of these small molecules. Subsequent approvals of oncology small molecule drugs are also creating a steady stream of opportunities in the market. For instance, Pfizer’s Daurismo (glasdegib) received an approval for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients.
  • Availability of multiple immunomodulatory (IMD) agents, with comparable mechanism of action and different routes of administration or structures, can potentially provide useful alternative modalities for personalized cancer treatment. Such advances are likely to spur the demand for oncology small molecule drugs in the forthcoming years.
  • Pharma researchers are increasingly pushing the envelope to find novel therapies, and leveraging next-generation technology to introduce advanced oncology small molecule drugs in market, promising reliability of the treatment.
oncology small molecule drugs market 01

For more intelligence into the oncology small molecule drugs market, request for the report sample 

Key Challenges in the Oncology Small Molecule Drugs Market 

  • Stringent regulatory framework related to approvals of critical drugs, including oncology small molecule drugs, has been a longstanding factor delaying the entire approval process, and thus the subsequent launch of life-saving medicines. This has been particularly the scenario in Japan. The presence of stringent regulatory pathways for new molecules in various regions has become a key challenge limiting the growth of partakers in the oncology small molecule drugs market.
  • Continued dearth of cancer treatment drugs, with just 55 novel drugs receiving regulatory approval during 2012 – 2016, is also impeding the growth of oncology small molecule drugs market. Region-specific availability of over half of the approved cancer drugs due to high price point, lower healthcare spending capabilities of patients, and stringent regulations, continues to limit growth in the oncology small molecule drugs market.
  • Limited reimbursement coverage in many countries has been resulting into expensive cancer treatment, making it highly inaccessible to a sizeable patient population. Though the reimbursement scenario is being altered in several regions, it is not rapid enough to provide access to several expensive drugs.

Oncology Small Molecule Drugs Market – Additional Insight

Targeted Therapy Drugs – Most Promising Drug Class in Oncology Small Molecule Drugs Market

Growing traction for targeted therapy as a vital type of cancer treatment continues to expand the bandwidth of opportunities for the manufacturers of oncology small molecule drugs. Development, quicker regulatory approval, and subsequent adoption of small molecule drugs to block the process that aids cancer cells multiply and spread, continue to uplift the oncology small molecule drugs market. Furthermore, growing FDA approvals of oncology small molecule drugs, such as larotrectinib (Vitrakvi) as a type of targeted therapy that aims a specific genetic change known as NTRK fusion, continue to add gains into the market.

Oncology Small Molecule Drugs Market – Research Methodology

oncology small molecule drugs market taxonomy

An accurate methodology and holistic approach forms the foundation of the valuable information presented in the oncology small molecule drugs market. The Fact.MR study offers thorough information about the growth forecast of oncology small molecule drugs sector, along with a systematic breakdown of the determinants impacting the growth of the market.

In-depth primary as well as secondary research has been performed to accumulate and present incisive insights into the forecast analysis of oncology small molecule drugs market. The report on oncology small molecule drugs market has also undergone numerous validation tunnels to ensure that that information mentioned in the report is unique and one of its kind.

Request Methodology of this Report.

1. Executive Summary
    1.1. Global Market Outlook
    1.2. Market Trends
    1.3. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Key Market Trends
    3.1. Key Trends Impacting the Market
    3.2. Product Innovation / Development Trends
4. Key Success Factors
    4.1. Key Regulations
    4.2. Epidemiology of Various Cancer Types, By Region
    4.3. Pipeline Assessment
5. Global Oncology Small Molecule Drug Market (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
    5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
        5.2.1. Y-o-Y Growth Trend Analysis
        5.2.2. Absolute $ Opportunity Analysis
6. Market Background
    6.1. Macro-Economic Factors
        6.1.1. Global GDP Growth Outlook
        6.1.2. Increasing R & D Expenditure
    6.2. Forecast Factors - Relevance & Impact
        6.2.1. Increasing Prevalence of Cancer
        6.2.2. Increasing Early Diagnosis Rate of Cancer
        6.2.3. Increasing Treatment Seeking Rate 
        6.2.4. Increasing Availability of Treatment Options for Cancer
        6.2.5. Adoption of Small Molecule in Oncology
    6.3. Market Dynamics
        6.3.1. Drivers
        6.3.2. Restraints
        6.3.3. Opportunity Analysis
7. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, By Drug Class 
    7.1. Introduction / Key Findings
    7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2014 - 2018
    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2019 - 2029
        7.3.1. Chemotherapy Drugs
            7.3.1.1. Alkylating Agents 
            7.3.1.2. Antimetabolites
            7.3.1.3. Other Drugs 
        7.3.2. Immunomodulating Drugs
        7.3.3. Targeted Therapy Drugs
            7.3.3.1. Proteasome Inhibitors 
            7.3.3.2. Tyrosine Kinase Inhibitors
            7.3.3.3. mTOR Inhibitors 
            7.3.3.4. Others
        7.3.4. Hormonal Therapy
    7.4. Market Attractiveness Analysis By Drug Class 
8. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, By Indication 
    8.1. Introduction / Key Findings
    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018
    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029
        8.3.1. Non-small Cell Lung Cancer (NSCLC)
        8.3.2. Renal Cell Carcinoma
        8.3.3. Breast Cancer
        8.3.4. Prostate Cancer
        8.3.5. Multiple Myeloma
        8.3.6. Melanoma
        8.3.7. Lymphoma
        8.3.8. Leukemia
        8.3.9. Others
    8.4. Market Attractiveness Analysis By Indication
9. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, By Route of Administration 
    9.1. Introduction / Key Findings
    9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2014 - 2018
    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2019 - 2029
        9.3.1. Oral
        9.3.2. Injectable
    9.4. Market Attractiveness Analysis By Route of Administration
10. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, by Distribution Channel
    10.1. Introduction / Key Findings
    10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014 - 2018
    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2019 - 2029
        10.3.1. Hospital Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. Specialty Clinics
        10.3.4. Online Pharmacies
    10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, by Region
    11.1. Introduction
    11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018
    11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029
        11.3.1. North America
        11.3.2. Latin America
        11.3.3. Europe
        11.3.4. East Asia
        11.3.5. South Asia
        11.3.6. Oceania
        11.3.7. Middle East and Africa (MEA)
    11.4. Market Attractiveness Analysis By Region
12. North America Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    12.1. Introduction
    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        12.3.1.  By Country
            12.3.1.1. U.S.
            12.3.1.2. Canada
        12.3.2. By Drug Class
        12.3.3. By Indication
        12.3.4. By Route of Administration
        12.3.5. By Distribution Channel
    12.4. Market Attractiveness Analysis
        12.4.1. By Country
        12.4.2. By Drug Class
        12.4.3. By Indication
        12.4.4. By Route of Administration
        12.4.5. By Distribution Channel
    12.5. Key Market Participants - Intensity Mapping
    12.6. Drivers and Restraints - Impact Analysis
13. Latin America Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    13.1. Introduction
    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        13.3.1.  By Country
            13.3.1.1. Brazil
            13.3.1.2. Mexico
            13.3.1.3. Rest of Latin America
        13.3.2. By Drug Class
        13.3.3. By Indication
        13.3.4. By Route of Administration
        13.3.5. By Distribution Channel
    13.4. Market Attractiveness Analysis
        13.4.1. By Country
        13.4.2. By Drug Class
        13.4.3. By Indication
        13.4.4. By Route of Administration
        13.4.5. By Distribution Channel
    13.5. Key Market Participants - Intensity Mapping
    13.6. Drivers and Restraints - Impact Analysis
14. Europe Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    14.1. Introduction
    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        14.3.1.  By Country
            14.3.1.1. Germany
            14.3.1.2. Italy
            14.3.1.3. France
            14.3.1.4. U.K.
            14.3.1.5. Spain
            14.3.1.6. BENELUX
            14.3.1.7. Russia
            14.3.1.8. Rest of Europe
        14.3.2. By Drug Class
        14.3.3. By Indication
        14.3.4. By Route of Administration
        14.3.5. By Distribution Channel
    14.4. Market Attractiveness Analysis
        14.4.1. By Country
        14.4.2. By Drug Class
        14.4.3. By Indication
        14.4.4. By Route of Administration
        14.4.5. By Distribution Channel
    14.5. Key Market Participants - Intensity Mapping
    14.6. Drivers and Restraints - Impact Analysis
15. South Asia Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    15.1. Introduction
    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        15.3.1.  By Country
            15.3.1.1. India
            15.3.1.2. Thailand
            15.3.1.3. Indonesia
            15.3.1.4. Malaysia
            15.3.1.5. Rest of South Asia
        15.3.2. By Drug Class
        15.3.3. By Indication
        15.3.4. By Route of Administration
        15.3.5. By Distribution Channel
    15.4. Market Attractiveness Analysis
        15.4.1. By Country
        15.4.2. By Drug Class
        15.4.3. By Indication
        15.4.4. By Route of Administration
        15.4.5. By Distribution Channel
    15.5. Key Market Participants - Intensity Mapping
    15.6. Drivers and Restraints - Impact Analysis
16. East Asia Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    16.1. Introduction
    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        16.3.1.  By Country
            16.3.1.1. China
            16.3.1.2. Japan
            16.3.1.3. South Korea
        16.3.2. By Drug Class
        16.3.3. By Indication
        16.3.4. By Route of Administration
        16.3.5. By Distribution Channel
    16.4. Market Attractiveness Analysis
        16.4.1. By Country
        16.4.2. By Drug Class
        16.4.3. By Indication
        16.4.4. By Route of Administration
        16.4.5. By Distribution Channel
    16.5. Key Market Participants - Intensity Mapping
    16.6. Drivers and Restraints - Impact Analysis
17. Oceania Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    17.1. Introduction
    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        17.3.1.  By Country
            17.3.1.1. Australia
            17.3.1.2. New Zealand
        17.3.2. By Drug Class
        17.3.3. By Indication
        17.3.4. By Route of Administration
        17.3.5. By Distribution Channel
    17.4. Market Attractiveness Analysis
        17.4.1. By Country
        17.4.2. By Drug Class
        17.4.3. By Indication
        17.4.4. By Route of Administration
        17.4.5. By Distribution Channel
    17.5. Key Market Participants - Intensity Mapping
    17.6. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    18.1. Introduction
    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        18.3.1.  By Country
            18.3.1.1. GCC Countries
            18.3.1.2. Turkey
            18.3.1.3. Northern Africa
            18.3.1.4. South Africa
            18.3.1.5. Rest of Middle East and Africa
        18.3.2. By Drug Class
        18.3.3. By Indication
        18.3.4. By Route of Administration
        18.3.5. By Distribution Channel
    18.4. Market Attractiveness Analysis
        18.4.1. By Country
        18.4.2. By Drug Class
        18.4.3. By Indication
        18.4.4. By Route of Administration
        18.4.5. By Distribution Channel
    18.5. Key Market Participants - Intensity Mapping
    18.6. Drivers and Restraints - Impact Analysis
19. Market Structure Analysis
    19.1. Market Analysis by Tier of Companies 
    19.2. Market Share Analysis of Top Players
    19.3. Market Presence Analysis
        19.3.1. By Regional footprint of Players
        19.3.2. Product & Channel foot print by Players
20. Competition Analysis
    20.1. Competition Dashboard
    20.2. Competition Benchmarking
    20.3. Competition Deep Dive 
        20.3.1. Novartis AG
            20.3.1.1. Overview
            20.3.1.2. Product Portfolio
            20.3.1.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.1.4. Sales Footprint
            20.3.1.5. Strategy Overview
                20.3.1.5.1. Marketing Strategy
                20.3.1.5.2. Product Strategy
                20.3.1.5.3. Channel Strategy
        20.3.2. Pfizer Inc.
            20.3.2.1. Overview
            20.3.2.2. Product Portfolio
            20.3.2.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.2.4. Sales Footprint
            20.3.2.5. Strategy Overview
                20.3.2.5.1. Marketing Strategy
                20.3.2.5.2. Product Strategy
                20.3.2.5.3. Channel Strategy
        20.3.3. Amgen Inc.
            20.3.3.1. Overview
            20.3.3.2. Product Portfolio
            20.3.3.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.3.4. Sales Footprint
            20.3.3.5. Strategy Overview
                20.3.3.5.1. Marketing Strategy
                20.3.3.5.2. Product Strategy
                20.3.3.5.3. Channel Strategy
        20.3.4. F. Hoffman - La Roche Ltd. (Genentech, Inc.)
            20.3.4.1. Overview
            20.3.4.2. Product Portfolio
            20.3.4.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.4.4. Sales Footprint
            20.3.4.5. Strategy Overview
                20.3.4.5.1. Marketing Strategy
                20.3.4.5.2. Product Strategy
                20.3.4.5.3. Channel Strategy
        20.3.5. Eli Lilly and Company
            20.3.5.1. Overview
            20.3.5.2. Product Portfolio
            20.3.5.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.5.4. Sales Footprint
            20.3.5.5. Strategy Overview
                20.3.5.5.1. Marketing Strategy
                20.3.5.5.2. Product Strategy
                20.3.5.5.3. Channel Strategy
        20.3.6. Sanofi S.A. (Genzyme Corporation)
            20.3.6.1. Overview
            20.3.6.2. Product Portfolio
            20.3.6.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.6.4. Sales Footprint
            20.3.6.5. Strategy Overview
                20.3.6.5.1. Marketing Strategy
                20.3.6.5.2. Product Strategy
                20.3.6.5.3. Channel Strategy
        20.3.7. Bristol-Myers Squibb Company
            20.3.7.1. Overview
            20.3.7.2. Product Portfolio
            20.3.7.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.7.4. Sales Footprint
            20.3.7.5. Strategy Overview
                20.3.7.5.1. Marketing Strategy
                20.3.7.5.2. Product Strategy
                20.3.7.5.3. Channel Strategy
        20.3.8. AbbVie Inc.
            20.3.8.1. Overview
            20.3.8.2. Product Portfolio
            20.3.8.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.8.4. Sales Footprint
            20.3.8.5. Strategy Overview
                20.3.8.5.1. Marketing Strategy
                20.3.8.5.2. Product Strategy
                20.3.8.5.3. Channel Strategy
        20.3.9. Bayer AG
            20.3.9.1. Overview
            20.3.9.2. Product Portfolio
            20.3.9.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.9.4. Sales Footprint
            20.3.9.5. Strategy Overview
                20.3.9.5.1. Marketing Strategy
                20.3.9.5.2. Product Strategy
                20.3.9.5.3. Channel Strategy
        20.3.10. Incyte Corporation
            20.3.10.1. Overview
            20.3.10.2. Product Portfolio
            20.3.10.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.10.4. Sales Footprint
            20.3.10.5. Strategy Overview
                20.3.10.5.1. Marketing Strategy
                20.3.10.5.2. Product Strategy
                20.3.10.5.3. Channel Strategy
        20.3.11. Celgene Corporation
            20.3.11.1. Overview
            20.3.11.2. Product Portfolio
            20.3.11.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.11.4. Sales Footprint
            20.3.11.5. Strategy Overview
                20.3.11.5.1. Marketing Strategy
                20.3.11.5.2. Product Strategy
                20.3.11.5.3. Channel Strategy
        20.3.12. AstraZeneca plc
            20.3.12.1. Overview
            20.3.12.2. Product Portfolio
            20.3.12.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.12.4. Sales Footprint
            20.3.12.5. Strategy Overview
                20.3.12.5.1. Marketing Strategy
                20.3.12.5.2. Product Strategy
                20.3.12.5.3. Channel Strategy
        20.3.13. Exelixis Inc.
            20.3.13.1. Overview
            20.3.13.2. Product Portfolio
            20.3.13.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.13.4. Sales Footprint
            20.3.13.5. Strategy Overview
                20.3.13.5.1. Marketing Strategy
                20.3.13.5.2. Product Strategy
                20.3.13.5.3. Channel Strategy
        20.3.14. Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Ltd)
            20.3.14.1. Overview
            20.3.14.2. Product Portfolio
            20.3.14.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.14.4. Sales Footprint
            20.3.14.5. Strategy Overview
                20.3.14.5.1. Marketing Strategy
                20.3.14.5.2. Product Strategy
                20.3.14.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology

List of Tables
Table 01A: Funding by Research Areas 2018 (US$ Millions)
Table 01B: Funding by Research Areas 2018 (US$ Millions)
Table 02: Global Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 03: Global Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 04: Global Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 05: Global Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 06: Global Oncology Small Molecule Drugs Market Value (US$ Mn) by Region, 2014 – 2029
Table 07: North America Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 08: North America Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 09: North America Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 10: North America Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 11: North America Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 12: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 13: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 14: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 15: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 16: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 17: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 18: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 19: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 20: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 21: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 22: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 23: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 24: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 25: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 26: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 27: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 28: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 29: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 30: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 31: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 32: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 33: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 34: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 35: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 36: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 37: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) by Country, 2014 – 2029
Table 38: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 39: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 40: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 41: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 42: China Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 43: China Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 44: China Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 45: China Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 46: India Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 47: India Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 48: India Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 49: India Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029
Table 50: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) by Drug Class, 2014 – 2029
Table 51: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) by Indication, 2014 – 2029
Table 52: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) by Route of Administration, 2014 – 2029
Table 53: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) by Distribution Channel, 2014 – 2029

 

List of Figures
Figure 01: Global Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 02: Global Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 03: Global Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 04: Global Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 05: Global Oncology Small Molecule Drugs Market Value Share By Region (2019E)
Figure 06: Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2014–2029
Figure 07: Oncology Small Molecule Drugs Market Absolute $ Opportunity (US$ Mn), 2018–2029
Figure 08: Global Oncology Small Molecule Drugs Market Analysis by Drug Class–2019 & 2029
Figure 09: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Projections by Drug Class, 2019–2029
Figure 10: Global Oncology Small Molecule Drugs Market Attractiveness Analysis by Drug Class
Figure 11: Global Oncology Small Molecule Drugs Market Analysis by Indication–2019 & 2029
Figure 12: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Projections by Indication, 2019–2029
Figure 13: Global Oncology Small Molecule Drugs Market Attractiveness Analysis by Indication
Figure 14: Global Oncology Small Molecule Drugs Market Analysis by Route of Administration–2019 & 2029
Figure 15: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Projections by Route of Administration, 2019–2029
Figure 16: Global Oncology Small Molecule Drugs Market Attractiveness Analysis by Route of Administration
Figure 17: Global Oncology Small Molecule Drugs Market Analysis by Distribution Channel–2019 & 2029
Figure 18: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Projections by Distribution Channel, 2019–2029
Figure 19: Global Oncology Small Molecule Drugs Market Attractiveness Analysis by Distribution Channel
Figure 20: Global Oncology Small Molecule Drugs Market Analysis by Region–2019 & 2029
Figure 21: Global Oncology Small Molecule Drugs Market Y-o-Y Growth Projections by Region, 2019–2029
Figure 22: Global Oncology Small Molecule Drugs Market Attractiveness Analysis by Region
Figure 23: North America Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 24: North America Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 25: North America Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 26: North America Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 27: North America Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 28: North America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 29: North America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 30: North America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 31: North America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 32: North America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 33: North America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 34: North America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 35: North America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 36: North America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 37: North America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 38: North America Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 39: North America Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 40: North America Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 41: North America Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 42: North America Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 43: Latin America Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 44: Latin America Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 45: Latin America Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 46: Latin America Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 47: Latin America Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 48: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 49: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 50: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 51: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 52: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 53: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 54: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 55: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 56: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 57: Latin America Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 58: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 59: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 60: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 61: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 62: Latin America Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 63: Europe Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 64: Europe Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 65: Europe Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 66: Europe Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 67: Europe Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 68: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 69: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 70: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 71: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 72: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 73: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 74: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 75: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 76: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 77: Europe Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 78: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 79: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 80: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 81: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 82: Europe Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 83: South Asia Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 84: South Asia Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 85: South Asia Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 86: South Asia Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 87: South Asia Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 88: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 89: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 90: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 91: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 92: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 93: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 94: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 95: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 96: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 97: South Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 98: South Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 99: South Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 100: South Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 101: South Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 102: South Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 103: East Asia Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 104: East Asia Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 105: East Asia Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 106: East Asia Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 107: East Asia Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 108: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 109: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 110: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 111: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 112: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 113: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 114: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 115: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 116: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 117: East Asia Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 118: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 119: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 120: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 121: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 122: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 123: Oceania Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 124: Oceania Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 125: Oceania Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 126: Oceania Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 127: Oceania Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 128: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 129: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 130: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 131: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 132: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 133: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 134: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 135: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 136: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 137: Oceania Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 138: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 139: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 140: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 141: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 142: Oceania Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 143: MEA Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 144: MEA Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 145: MEA Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 146: MEA Oncology Small Molecule Drugs Market Value Share By Distribution Channel (2019E)
Figure 147: MEA Oncology Small Molecule Drugs Market Value Share By Country (2019E)
Figure 148: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 149: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 150: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 151: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 152: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 153: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 154: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 155: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 156: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 157: MEA Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 158: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 159: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 160: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 161: MEA Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 162: East Asia Oncology Small Molecule Drugs Market Attractiveness Analysis By Country, 2019–2029 
Figure 163: Emerging Countries Market Value Share (2019) 
Figure 164: Emerging Countries Oncology Small Molecule Drugs Market Value (US$ Bn), By Key Countries, 2014-2029
Figure 165: China Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 166: China Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 167: China Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 168: China Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 169: China Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 170: China Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 171: China Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 172: China Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 173: China Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 174: China Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 175: China Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 176: China Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 177: China Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 178: China Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 179: China Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 180: China Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 181: China Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 182: India Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 183: India Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 184: India Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 185: India Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 186: India Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2029
Figure 187: India Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 188: India Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 189: India Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 190: India Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 191: India Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 192: India Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 193: India Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 194: India Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 195: India Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 196: India Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 197: India Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 198: India Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029 
Figure 199: Brazil Oncology Small Molecule Drugs Market Value Share By Drug Class (2019E)
Figure 200: Brazil Oncology Small Molecule Drugs Market Value Share By Route of Administration (2019E)
Figure 201: Brazil Oncology Small Molecule Drugs Market Value Share By Indication (2019E)
Figure 202: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018
Figure 203: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029
Figure 204: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Chemotherapy Drugs
Figure 205: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Chemotherapy Drugs 
Figure 206: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Immunomodulating Drugs 
Figure 207: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Immunomodulating Drugs 
Figure 208: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Targeted Therapy Drugs
Figure 209: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Targeted Therapy Drugs
Figure 210: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) Analysis, 2014–2018, By Hormonal Therapy
Figure 211: Brazil Oncology Small Molecule Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2029, By Hormonal Therapy
Figure 212: Brazil Oncology Small Molecule Drugs Market Attractiveness Analysis By Drug Class, 2019–2029 
Figure 213: Brazil Oncology Small Molecule Drugs Market Attractiveness Analysis By Indication, 2019–2029 
Figure 214: Brazil Oncology Small Molecule Drugs Market Attractiveness Analysis By Route of Administration, 2019–2029 
Figure 215: Brazil Oncology Small Molecule Drugs Market Attractiveness Analysis By Distribution Channel, 2019–2029

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development